Imugene Limited (ASX:IMU) beefs up its leadership team with new appointment

Highlights

• Imugene Limited (ASX:IMU) has made a crucial appointment to its leadership team.
• The company has appointed Mike Tonroe to serve its newly created in-house position of CFO.
• Mr Tonroe holds years of experience in international finance leadership within the biopharmaceutical industry.

Committed to achieving its commercial and clinical milestones, ASX-listed Imugene Limited (ASX:IMU) has further strengthened its leadership team to steer the company’s growth. The clinical stage immuno-oncology company has brought Mike Tonroe onboard to take charge of the newly created in-house role of Chief Financial Officer (CFO). Mr Tonroe is expected to begin his term as the company’s CFO in early September 2022, soon after the transition arrangements are finalised.

Since June 2022, this is the third major appointment made by Imugene. IMU appointed clinical scientist Dr. Sharon Yavrom to serve as its Executive Director, Clinical Scientist on 04 July. Prior to that, the company had welcomed Dr. Yanghee Woo to join its Scientific Advisory Board (SAB) in early June.

Who is Mike Tonroe?

Armed with years of experience in international finance leadership, Mike Tonroe is well acquainted with the biopharmaceutical industry.  He has held several leadership positions in multiple firms across the US, UK, Canada, Australia and Hong Kong.

Previously, he has served as CFO as well as Company Secretary at Genetic Technologies Ltd., Opthea Limited, and Australian Synchotron Company Ltd, wherein he managed the US IPO and NASDAQ listing, merger and acquisition, capital raising, restructuring, and finance functions of the companies.

Over the years, he has worked in diverse sectors, such as technology, travel, and energy. He has also served at some of the leading accounting firms, such as Deloitte and KPMG.

Mr Tonroe has done his Bachelor of Arts (Honours) in Business Studies from one of the renowned universities of the United Kingdom, Buckingham University. Also, he is a Fellow of the Institute of Chartered Accountants in England & Wales and accredited under Australian Institute of Company Directors.

Read here for information on Imugene’s presentation of new PD1-Vaxx data at this year’s World Conference on Lung Cancer (WCLC 2022).

Welcome note by Imugene’s M.D. & CEO, Ms Leslie Chong:

 
Image Source: ©2022 Kalkine Media®; Data Source: Company Announcement (18 July 2022)

Imugene shares are trading at A$0.25, as at 10:30 AM AEST.

Want to know what lies ahead for Imugene Limited in 2022? Click here.